Good Therapeutics is developing new technology for self-regulating drugs that will provide therapeutic activity when and where it is needed.

Biotechnology

Good Therapeutics

Rhonda Knudsen has over 25 years of work experience in the field of Human Resources and Operations. Rhonda began their career in 1995 as an HR Generalist at Darwin Molecular. In 2000, they moved on to become an HR Manager at Mercata, Inc. Rhonda then worked as the Director of HR & Business Administration at Blue Heron Biotech LLC from 2001 to 2003. In 2003, they became the Director of Human Resources at the Institute for Systems Biology. In 2006, they moved on to become the Director of Sales at Cytopeia, Inc. In 2008, they became the Manager of Sales Support Programs at BD. In 2017, they transitioned to become the Manager of Sales Operations at Olympus Corporation of the Americas. In 2021, they moved on to become the Director of Operations at Good Therapeutics, Inc. and is currently in the same role at Bonum Therapeutics.

Rhonda Knudsen has a Master of Business Administration (MBA) in Global Management from City University of Seattle, a Certification in Teaching English as a Second or Foreign Language/ESL Language Instructor from Seattle University, and a Bachelor of Arts (B.A.) in French from the University of Montana.

Rhonda Knudsen

Lynn Amon

Dr. David Bienvenue leverages over 20 years of protein development experience to advance Bonum’s candidates toward the clinic. He joined Good Therapeutics in 2021 and then transitioned to Bonum Therapeutics after the acquisition by Roche in 2022.  He previously served as Vice President of Protein Sciences, Analytical and Process Development at Aptevo Therapeutics. He led the Aptevo Early Product Development Team to develop novel bispecific proteins for immuno-oncology and is an inventor on multiple Aptevo patents. His approach to clinical lead selection emphasizes the importance of evaluating developability to de-risk candidates.

Dr. Bienvenue also held positions as Director of Protein Sciences at VLST Corporation and purification development lead at Dendreon Corporation. At Dendreon, he participated in the development of Provenge, the first FDA-approved immunotherapy for prostate cancer. He obtained his PhD in Biochemistry from Utah State University.

David Bienvenue

Samuel is a Principal at Digitalis, where he focuses on early-stage life sciences investments and company creation activities.

Prior to Digitalis, Samuel was a member of the healthcare practice at the Boston Consulting Group. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University.

Samuel Bjork

Mitchell Mutz, Ph.D., is an accomplished biotech serial entrepreneur, venture investor, and inventor.  Since 2021, he has served as Entrepreneur Partner at Vivo Capital. Mitchell focuses on early-stage investment opportunities in therapeutics. He is currently on the board of Epi Biologics.

Prior to joining Vivo, Mitchell was Senior Investment Director at the Roche Venture Fund, a $750M Swiss corporate venture fund that invests for financial return. Deals led for Roche included Pandion Therapeutics (acquired by Merck), Enliven Therapeutics, Good Therapeutics (acquired by Roche), Jasper Therapeutics (NASDAQ:JSPR), and Kumquat Biosciences.

Previously, Mitchell was a co-founder, president, chief scientific officer, and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company and Stanford University spinout developing small molecule therapeutics to treat invasive fungal infections. Mitchell led the company’s R&D  and financing efforts, and helped grow the company from early preclinical discovery to the clinical stage. Amplyx attracted over $140M in venture financing and was acquired by Pfizer after completing a successful Phase 2 clinical trial.  Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company employing acoustic physics to enable liquid handling for drug discovery as well as synthetic biology.  Labcyte attracted over $80M in venture financing and was acquired by Beckman Coulter.

Mitchell earned a Ph.D. in chemistry from the University of Rochester, a diploma in orchestral studies from the University of London, and a B.A. in chemistry with high honors from Oberlin College. He spent one year studying towards a Ph.D. in the Department of Cellular and Developmental Biology at Harvard University. Mitchell is also an inventor of 38 issued patents.

Mitchell Mutz

Dr. Justin Killebrew brings over 15 years of research and drug discovery experience in the areas of oncology and immunology. He joined Good Therapeutics in 2018 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022. Before joining Good, he was Director of Discovery Biology at Silverback Therapeutics, where he oversaw in vitro and in vivo research in support of their lead ADC program.

Prior to Silverback, he held positions of increasing responsibility within the research organization at Bristol-Myers Squibb, where he advanced multiple therapeutic programs within the areas of Immuno-Oncology and Immunoscience. Dr. Killebrew received his Ph.D. in Immunology from the University of Washington.

Justin Killebrew

Dr. Neela Patel is a scientist and business development executive with 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation. Prior to Bonum, as Chief Business Development Office at Good Therapeutics, she co-led the Roche transaction and spinout of Bonum. Previously, as Executive Director of Corporate Development at Seagen, she played an integral role in deal sourcing and execution of collaborations, licenses and acquisitions to build the pipeline, including agreements with Pieris and FivePrime. Dr. Patel’s sourcing and diligence at AbbVie resulted in more than twenty-five executed deals including collaborations, licensing, and participation in consortia. Dr. Patel spent the first 16 years of her career in drug discovery with positions of increasing responsibility, advancing small molecules and biologics from target ID and validation through IND filing at Poniard Pharmaceuticals, Genentech, SUGEN/Pharmacia, and Roche Bioscience.

Dr. Patel completed her post-doctoral training at the DNAX Research Institute after receiving her Ph.D. in Molecular Biology from UCLA. She graduated Phi Beta Kappa from Stanford with a B.S. in Biology and a B.A. in Humanities with Honors.

Neela Patel

Dr. Diane Hollenbaugh is a drug discovery scientist and executive with more than 25 years of experience in biological research, and discovery and early development.  She joined Good Therapeutics in 2019 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022.  Prior to Good, she was Executive Director, Immuno-oncology Discovery at AbbVie where she oversaw the growth of IO efforts, including early discovery and translational science, licensing partnerships, and five discovery projects brought to IND. Prior to AbbVie, she has experience at multiple large and small companies, including BMS, Medarex, FivePrime Therapeutics and Schering-Plough/Merck.

She received her PhD from the California Institute of Technology Division of Chemistry and Chemical Engineering following her BS in Chemistry from the University of Washington.

Diane Hollenbaugh

Dr. John Mulligan is a scientist and executive with 30 years of experience in research management, drug discovery, company formation and business development. Prior to founding Good Therapeutics he was the founder and CEO of Glycostasis, where he invented a glucose-responsive insulin technology and sold the company to Eli Lilly in 2015. As the Director of Genomics at Darwin Molecular he pioneered a genetic approach to target discovery that yielded an osteoporosis drug target. Romosozumab, an antibody to this target, was recently approved in the US, Europe and Japan for the treatment of osteoporosis.

After leaving Darwin Molecular he founded Blue Heron Biotechnology, an early synthetic biology company that was acquired by Origene in 2010, and co-founded the International Gene Synthesis Consortium, an industry group focused on biosecurity and the appropriate regulation of synthetic biology. He received a BS in Biology from MIT, then spent twelve years at Stanford as a Ph.D student with Sharon Long in the Department of Biology, a postdoctoral fellow with Ronald W. Davis in the Department of Biochemistry, and a Research Assistant Professor in the Department of Genetics where he helped set up the Stanford Genome Technology Center.

John Mulligan

Monique is a Senior Investment Director at the Roche Venture Fund. Former roles include serving as the Chief Operating Officer at Inthera Bioscience AG, a previous Director position at Roche Venture Fund from 2009 to 2018, and a principal position with BankInvest's BioMedical Ventures Group in Copenhagen. In addition, Monique's background includes several years in Roche's Pharma business development group, and various other positions in academia, biotech and venture capital, both in Switzerland and the San Francisco Bay Area. Monique holds a M.Sc. in microbiology from the University of Zurich (Switzerland) and an MBA from the University of San Francisco.

Monique Schiersing

John has three decades of drug development and investing experience in life sciences. He joined RiverVest in 2008 and focuses on early-stage biotechnology investments. Currently, John serves on the boards of Allakos, Inc. (IPO), OncoResponse, Inc., Good Therapeutics, Arch Oncology, Inc., and Adarza Biosystems, Inc. He previously served on the boards of Lumena Pharmaceuticals, Inc. (acquired by Shire Plc), Otonomy, Inc. (IPO) and ZS Pharma, Inc. (acquired by AstraZeneca Plc).

Prior to RiverVest, John was president and CEO and a director of Kalypsys, Inc. from 2003 to 2008, and an executive at Searle/Pharmacia (Pfizer, Inc.) from 1987 to 2003, where he held increasingly responsible positions, including the global head of Research. John helped establish the groundwork for studies that led to the commercialization of several major products, including DayPro, Arthrotec, and Celebrex, one of the leading pharmaceuticals to treat arthritis. He also served on the boards of IDM Pharma, Inc. (acquired by Takeda America Holdings, Inc.), Epimmune, Inc., and Keel Pharmaceuticals, Inc. Prior to 1987, John was a senior scientist at E.I. DuPont de Nemours and Company, a member of the Basel Institute for Immunology in Basel, Switzerland, and a research associate in the Department of Microbiology and Immunology at Washington University in St. Louis.

John holds a Ph.D. in Immunology from the University of Chicago and a B.S. in Biology from Northern Illinois University. He has co-authored more than 70 published, peer-reviewed scientific papers, and holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease.

John McKearn

Nicholas Walrod is a Managing Director and co-founder of 3x5 Partners, a growth equity venture capital firm in Portland, OR. The firm makes investments in the Life Sciences and Climate Solutions (water, agriculture, energy and natural resource) sectors. He brings 20 years of experience as an investor, board member, and strategic partner to the service of ground-breaking companies in the resource and medical technologies fields. As a General Partner of three Funds and many special purpose vehicles, Nick serves on the board of directors of Fishpeople Seafood, Smart Wires, Rubicon Global, Good Therapeutics, Fervo Energy, and SOURCE Global. Previously, Nick sourced and managed hedge fund and private equity relationships at Arnerich Massena.

Mr. Walrod holds an A.B. in public policy studies from Duke University. He lives in Portland, OR with his wife and three children, and also owns Dancing Moon Farm, an organic vegetable and flower farm in Hood River, OR.

Nicholas Walrod

Karl D. Handelsman is the founder and Managing Partner, Codon Capital, and a key contributor and builder in the US biotech innovation ecosystem. Through his network and leadership, he drives Codon Capital to intensely focus on the best biotech targets for investments. The key criteria are the team, the technology, and the investment syndicate. Karl is looking for what he calls “an unfair technology advantage, a team uniquely qualified around that technology opportunity, and multiple routes to success.” Without knowing the technology and the team, he notes, the what if should look "impossible" to the outside world.

The key: find something disruptive, and be confident that technical success will generate a great return on invested capital, and as importantly, make the stock options valuable for those doing the work. Repeat entrepreneurs who can build even bolder startups are the limiting resource, and Karl considers it a privilege to work with them as an investor.

Karl's disciplined approach includes coaching at various incubators and teaching healthcare entrepreneurs, e.g., NSF I-Corps Biotech at the National institutes of Health, National Cancer Institute, Stanford, UCSF, and Imperial College London. He was a personal sponsor of SynBioBeta 1.0, and consulting advisor for Stanford SPARK, University of California Catalyst program, and the California Life Sciences Institute FAST program. He is a member of Life Science Angels. Karl has developed this process to build a better VC, and to support better entrepreneurship in biotech.

Karl received advanced degrees in business from MIT Sloan School of Business (MBA) and in science from Harvard Medical School (MS/Genetics). He has an undergraduate degree from Boston University (Trustee Scholar) in Biology. Prior to venture investing, he worked in Business Development (Tularik and Millenium). In May 2013, he founded Codon Capital after 14 years as a managing director at a major venture fund.

Leadership Team

About

Team members

Other teams at Good Therapeutics

Board of Directors

CEO and Executive Team

Discover similar companies